Publications by authors named "C Cartier"

Epistaxis greatly affects patients with hereditary hemorrhagic telangiectasia (HHT). Although few systemic treatment exist, nintedanib, is a good candidate thanks to its anti-angiogenic activity. Our main objective was to evaluate the efficacy of oral nintedanib on epistaxis duration in HHT patients with moderate to severe epistaxis.

View Article and Find Full Text PDF

Supplementing a fishmeal-free diet with yeast extract improves rainbow trout (Oncorhynchus mykiss) growth performance and modulates the hepatic and intestinal transcriptomic response. These effects are often observed in the long term but are not well documented after short periods of fasting. Fasting for a few days is a common practice in fish farming, especially before handling the fish, such as for short sorting, tank transfers, and vaccinations.

View Article and Find Full Text PDF
Article Synopsis
  • Human exposure to foodborne inorganic nanoparticles (NPs), like titanium dioxide (TiO), raises concerns about health risks, necessitating better testing methods.
  • The study utilized enteroid-derived monolayers (EDMs) from mouse intestinal organoids as an in vitro model to assess the toxicity of TiO, showing clear responses to varying doses.
  • Findings indicated that TiO exposure led to increased cell differentiation markers, apoptosis, genotoxicity, and disrupted gene expressions related to gut health, establishing EDMs as a reliable model for testing foodborne NPs' effects on the intestinal barrier.
View Article and Find Full Text PDF

Background: The increasing prevalence of food sensitivities has been attributed to changes in gut microenvironment; however, ubiquitous environmental triggers such as inorganic nanoparticles (NPs) used as food additives have not been thoroughly investigated.

Objectives: We explored the impact of the NP-structured food-grade silicon dioxide () on intestinal immune response involved in oral tolerance (OT) induction and evaluated the consequences of oral chronic exposure to this food-additive using a mouse model of OT to ovalbumin (OVA) and on gluten immunopathology in mice expressing the celiac disease risk gene, HLA-DQ8.

Methods: Viability, proliferation, and cytokine production of mesenteric lymph node (MLN) cells were evaluated after exposure to .

View Article and Find Full Text PDF
Article Synopsis
  • Bevacizumab, a monoclonal antibody, is used to treat hereditary hemorrhagic telangiectasia (HHT), but this is the first randomized trial investigating its effectiveness.
  • In a double-blind study involving 24 patients, those treated with bevacizumab showed a greater decrease in blood transfusions compared to the placebo group, with significant improvements in hemoglobin levels over six months.
  • Despite some positive results, the trial was underpowered, meaning more research is needed to confirm that bevacizumab helps reduce the need for blood transfusions in HHT patients, especially in those exposed to higher doses.
View Article and Find Full Text PDF